-

12:05:29 PM

Latest INMB Stock Market News

INMB - INmune Bio Inc

07/28/21 4:05 PM

Nasdaq : INMB

conferencesearnings

INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight

RHEA-AI

neutral

07/26/21 8:30 AM

Nasdaq : INMB

clinical trial

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data

Phase 2 study of XPro TM will be a six -month , blinded , randomized , placebo-controlled trial in 168 patients with m ild A lzheimer’s disease and biomarkers of inflammation . Additional analysis from the P hase 1b study of XPro TM demonstrates improvements in w hite matter analytics within three

RHEA-AI

neutral

07/22/21 11:53 AM

Nasdaq : INMB

acquisition

INmune Bio acquires LUMICKS' z-Movi® Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatments

LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bio (NASDAQ: INMB).INmune

RHEA-AI

neutral

07/19/21 8:30 AM

Nasdaq : INMB

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association International Conference 2021

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing

RHEA-AI

neutral

07/14/21 9:02 AM

Nasdaq : INMB

offering

INMUNE BIO, INC. ANNOUNCES $40 MILLION REGISTERED DIRECT OFFERING

INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune Bio”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it has entered into a

RHEA-AI

neutral

07/12/21 8:00 AM

Nasdaq : INMB

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology

RHEA-AI

neutral

06/14/21 4:01 PM

Nasdaq : INMB

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing

RHEA-AI

very positive

06/02/21 9:00 AM

Nasdaq : INMB

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that the United States Adopted Name

RHEA-AI

neutral

05/24/21 9:00 AM

Nasdaq : INMB

conferences

INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021

INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that RJ Tesi, MD, chief executive officer, has

RHEA-AI

neutral

05/05/21 4:15 PM

Nasdaq : INMB

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease,

RHEA-AI

neutral

INMB Data

industryResearch and Development in Biotechnology
websitewww.inmunebio.com
ceo
security nameINmune Bio Inc
issue typecs
sectorProfessional, Scientific, and Technical Services
sic code2836
employees
tagsMedical Specialties,Biotechnology,Health Technology
address
address2
state
city
zip
country
phone

INMB Description:

INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.